Dr. Manuel Kaulich studied biotechnology and molecular life science at the University of Lübeck and obtained his PhD in the laboratory of Erich A. Nigg at Max Planck Institute of Biochemistry in Martinsried (Germany) and the Biozentrum in Basel (Switzerland), respectively. In 2011 he moved to the group of Steven F. Dowdy at the University of California in San Diego, where he first became interested in gene editing technologies. Since December 2015, Manuel is an independent group leader at the Institute of Biochemistry II at Goethe University Frankfurt. Manuel's academic interest lies in cell cycle entry regulation in the context of malignancy. He also developed a strong interest in the CRISPR/Cas9 and rAAV gene editing technologies and has developed technologies to efficiently perform targeted gene replacement in human cells. He is the lead inventor of the 3Cs technology which forms the key of Vivlion's IP portfolio. Together with Ivan Dikic, Manuel Kaulich heads the Frankfurt CRISPR/Cas9 Screening Center (FCSC) at Institute of Biochemistry II. This academic center serves the local research community with technical and bioinformatical expertise to perform gene knockouts for functional studies as well as large scale genome-wide and hypothesis-driven CRISPR/Cas-based screenings.